Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study
2008; Oxford University Press; Volume: 197; Issue: 8 Linguagem: Inglês
10.1086/586713
ISSN1537-6613
AutoresSean Emery, Jacqueline Neuhaus, Andrew Phillips, Abdel Babiker, Calvin Cohen, José M. Gatell, Pierre Marie Girard, Birgit Grund, Matthew Law, Marcelo Losso, Adrian Palfreeman, Robin Wood,
Tópico(s)HIV/AIDS drug development and treatment
ResumoBackgroundThe SMART study randomized 5472 human immunodeficiency virus (HIV)–infected patients with CD4+ cell counts >350 cells/μL to intermittent antiretroviral therapy (ART; the drug conservation [DC] group) versus continuous ART (the viral supression [VS] group). In the DC group, participants started ART when the CD4+ cell count was 350 cells/μL compared with <250 cells/μL may reduce both OD and serious non-AIDS events. These findings require validation in a large, randomized clinical trial Trial registrationClinicalTrials.gov identifier: NCT00027352
Referência(s)